DK1549353T3 - Anvendelse af alfa(1,3)galactosyltransferaseudtrykkende allogene tumorceller til vaccination mod tumorer - Google Patents

Anvendelse af alfa(1,3)galactosyltransferaseudtrykkende allogene tumorceller til vaccination mod tumorer

Info

Publication number
DK1549353T3
DK1549353T3 DK03779090.4T DK03779090T DK1549353T3 DK 1549353 T3 DK1549353 T3 DK 1549353T3 DK 03779090 T DK03779090 T DK 03779090T DK 1549353 T3 DK1549353 T3 DK 1549353T3
Authority
DK
Denmark
Prior art keywords
cells
tumor
tumor cells
galactosyltransferase
alpha
Prior art date
Application number
DK03779090.4T
Other languages
English (en)
Inventor
Charles J Link Jr
Tatiana Seregina
Gabriela Rossi
Original Assignee
Central Iowa Health System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Central Iowa Health System filed Critical Central Iowa Health System
Application granted granted Critical
Publication of DK1549353T3 publication Critical patent/DK1549353T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
DK03779090.4T 2002-10-09 2003-10-09 Anvendelse af alfa(1,3)galactosyltransferaseudtrykkende allogene tumorceller til vaccination mod tumorer DK1549353T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41734302P 2002-10-09 2002-10-09
PCT/US2003/032036 WO2004032865A2 (en) 2002-10-09 2003-10-09 Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase

Publications (1)

Publication Number Publication Date
DK1549353T3 true DK1549353T3 (da) 2010-07-12

Family

ID=32094006

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03779090.4T DK1549353T3 (da) 2002-10-09 2003-10-09 Anvendelse af alfa(1,3)galactosyltransferaseudtrykkende allogene tumorceller til vaccination mod tumorer

Country Status (13)

Country Link
US (5) US20040191229A1 (da)
EP (1) EP1549353B1 (da)
JP (1) JP4966496B2 (da)
CN (2) CN1756568A (da)
AT (1) ATE462449T1 (da)
AU (1) AU2003285863A1 (da)
CA (1) CA2501744C (da)
DE (1) DE60331933D1 (da)
DK (1) DK1549353T3 (da)
ES (1) ES2341335T3 (da)
HK (1) HK1215044A1 (da)
MX (1) MXPA05003705A (da)
WO (1) WO2004032865A2 (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE359084T1 (de) 1998-02-20 2007-05-15 Univ Miami Modifizierter hitzeschockprotein/peptidantigen komplex
CN1756568A (zh) 2002-10-09 2006-04-05 衣阿华中央卫生系统 使用表达α(1,3)－半乳糖基转移酶的同种异型肿瘤细胞的抗肿瘤免疫
US20050201993A1 (en) * 2002-10-09 2005-09-15 Link Charles J.Jr. Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
JP5623004B2 (ja) * 2004-10-25 2014-11-12 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 熱ショックをかけたメラノーマ細胞体が装填された樹状細胞
US7820628B2 (en) * 2005-02-22 2010-10-26 University Of Massachusetts Medical School Tumor lesion regression and conversion in situ into autologous tumor vaccines by compositions that result in anti-Gal antibody binding
US7850683B2 (en) * 2005-05-20 2010-12-14 Myoscience, Inc. Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US7713266B2 (en) * 2005-05-20 2010-05-11 Myoscience, Inc. Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US7998486B2 (en) 2006-10-25 2011-08-16 Newlink Genetics Corporation Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes
US9254162B2 (en) 2006-12-21 2016-02-09 Myoscience, Inc. Dermal and transdermal cryogenic microprobe systems
US8409185B2 (en) 2007-02-16 2013-04-02 Myoscience, Inc. Replaceable and/or easily removable needle systems for dermal and transdermal cryogenic remodeling
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US8298216B2 (en) 2007-11-14 2012-10-30 Myoscience, Inc. Pain management using cryogenic remodeling
US20100112702A1 (en) * 2008-02-25 2010-05-06 Klein Benjamin Y Method designed to divert glucose away from the glycolytic pathway
AU2009223838B2 (en) 2008-03-03 2012-07-26 The University Of Miami Allogeneic cancer cell-based immunotherapy
CA2718884C (en) 2008-03-20 2016-11-22 University Of Miami Heat shock protein gp96 vaccination and methods of using same
CA2725947A1 (en) * 2008-05-30 2009-12-03 Glycofi, Inc. Yeast strain for the production of proteins with terminal alpha-1,3-linked galactose
EP2358383A4 (en) * 2008-11-21 2011-11-23 Univ Miami HIV / VIS VACCINES FOR THE GENERATION OF MUCOUS AND SYSTEMIC IMMUNITY
WO2010075438A1 (en) 2008-12-22 2010-07-01 Myoscience, Inc. Integrated cryosurgical system with refrigerant and electrical power source
US20120220488A1 (en) * 2009-11-10 2012-08-30 Qinghong Li Heart aging biomarkers and methods of use
US20110150934A1 (en) * 2009-12-18 2011-06-23 University Of Notre Dame Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer
CN102917709B (zh) 2009-12-23 2018-04-24 格兰达利斯有限公司 弗林蛋白酶敲减和gm-csf增强的（fang）癌症疫苗
SG181881A1 (en) 2009-12-23 2012-07-30 Gradalis Inc Furin-knockdown bi-functional rna
CN105399833B (zh) * 2010-01-04 2019-09-06 Kj 生物科学有限公司 用于疫苗和诊断学的Dps融合蛋白
CN102286428A (zh) * 2011-06-04 2011-12-21 内蒙古医学院 一种在肿瘤细胞表面合成α-半乳糖苷表位并激活免疫细胞的方法
CN102716497A (zh) * 2011-07-07 2012-10-10 赵永祥 α1,3半乳糖基转移酶基因转染材料及其制备方法和应用
BR112014017175A8 (pt) 2012-01-13 2017-07-04 Myoscience Inc proteção de pele para remodelagem criogênica subdérmica para tratamentos cosméticos e outros
US9314290B2 (en) 2012-01-13 2016-04-19 Myoscience, Inc. Cryogenic needle with freeze zone regulation
EP2802278B1 (en) 2012-01-13 2016-12-07 Myoscience, Inc. Cryogenic probe filtration system
US9017318B2 (en) 2012-01-20 2015-04-28 Myoscience, Inc. Cryogenic probe system and method
CN102760208B (zh) * 2012-07-03 2015-07-29 清华大学 基于模拟疫苗的动态人工免疫故障诊断方法
WO2014064534A2 (en) 2012-10-05 2014-05-01 Chrontech Pharma Ab Injection needle, device, immunogenic compositions and method of use
US20140350536A1 (en) 2013-03-15 2014-11-27 Myoscience, Inc. Cryogenic Blunt Dissection Methods and Devices
WO2014146122A1 (en) 2013-03-15 2014-09-18 Myoscience, Inc. Methods and systems for treatment of occipital neuralgia
US9610112B2 (en) 2013-03-15 2017-04-04 Myoscience, Inc. Cryogenic enhancement of joint function, alleviation of joint stiffness and/or alleviation of pain associated with osteoarthritis
WO2014151423A1 (en) * 2013-03-15 2014-09-25 Newlink Genetics Corporation Carbohydrate-modified glycoproteins and uses thereof
US9295512B2 (en) 2013-03-15 2016-03-29 Myoscience, Inc. Methods and devices for pain management
AU2014265342A1 (en) * 2013-05-15 2016-01-21 Newlink Genetics Corporation Correlates of efficacy relating to tumor vaccines
US10130409B2 (en) 2013-11-05 2018-11-20 Myoscience, Inc. Secure cryosurgical treatment system
RU2714157C2 (ru) 2015-02-06 2020-02-12 Хит Байолоджикс, Инк. Вектор, коэкспрессирующий молекулы для вакцинации и костимулирующие молекулы
GB201505860D0 (en) * 2015-04-07 2015-05-20 Agalimmune Ltd Therapeutic compositions and methods of use for treating cancer
US11311327B2 (en) 2016-05-13 2022-04-26 Pacira Cryotech, Inc. Methods and systems for locating and treating nerves with cold therapy
WO2018071405A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
US11896653B2 (en) 2017-09-13 2024-02-13 Unm Rainforest Innovations Silicified cell replicas, methods of making, and methods of using
US11134998B2 (en) 2017-11-15 2021-10-05 Pacira Cryotech, Inc. Integrated cold therapy and electrical stimulation systems for locating and treating nerves and associated methods
JP2022542247A (ja) * 2019-07-24 2022-09-30 エスエルバイジェン インコ―ポレイテッド 不死化幹細胞株の製造方法およびその用途
CN115551537A (zh) 2019-12-03 2022-12-30 纽沃进公司 肿瘤细胞疫苗
WO2021139810A1 (en) * 2020-01-10 2021-07-15 The University Of Hong Kong Recombinant viruses expressing alpha-1, 3-galactosyltransferase and uses thereof
WO2021202449A1 (en) * 2020-03-30 2021-10-07 Unm Rainforest Innovations Nanoparticle-loaded silicified cells, methods of making, and methods of use
US20230000963A1 (en) * 2021-06-02 2023-01-05 Neuvogen, Inc. Tumor cell vaccines

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2185470C (en) 1994-03-15 2005-10-25 Uri Galili Compositions and methods for vaccines comprising .alpha.-galactosyl epitopes
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
JP2001517206A (ja) * 1996-08-16 2001-10-02 ザ ジョンズ ホプキンズ ユニヴァーシティ スクール オヴ メディシン 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
US5869035A (en) * 1996-11-13 1999-02-09 Human Gene Therapy Research Institute Methods and compositions for inducing complement destruction of tissue
WO2000009140A1 (en) * 1997-07-24 2000-02-24 Thomas Jefferson University Composition and method of using tumor cells
US7005126B1 (en) * 1999-06-08 2006-02-28 Human Gene Therapy Research Institute Method for tumor treatment using infusion of xenogeneic cells to induce hyperacute rejection and innocent bystander effect
US7101543B2 (en) * 2000-03-31 2006-09-05 Novarx Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells
WO2002042468A2 (en) * 2000-11-27 2002-05-30 Geron Corporation Glycosyltransferase vectors for treating cancer
CN1756568A (zh) 2002-10-09 2006-04-05 衣阿华中央卫生系统 使用表达α(1,3)－半乳糖基转移酶的同种异型肿瘤细胞的抗肿瘤免疫
US20050201993A1 (en) * 2002-10-09 2005-09-15 Link Charles J.Jr. Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase

Also Published As

Publication number Publication date
CN1756568A (zh) 2006-04-05
WO2004032865A2 (en) 2004-04-22
JP2006507267A (ja) 2006-03-02
JP4966496B2 (ja) 2012-07-04
ATE462449T1 (de) 2010-04-15
US8535658B2 (en) 2013-09-17
CN104911210A (zh) 2015-09-16
US20070014774A1 (en) 2007-01-18
US7763461B2 (en) 2010-07-27
ES2341335T3 (es) 2010-06-18
EP1549353B1 (en) 2010-03-31
CA2501744A1 (en) 2004-04-22
US20070014775A1 (en) 2007-01-18
US20110250233A1 (en) 2011-10-13
US20140037692A1 (en) 2014-02-06
CA2501744C (en) 2012-01-03
WO2004032865A9 (en) 2004-07-22
US20040191229A1 (en) 2004-09-30
HK1215044A1 (zh) 2016-08-12
AU2003285863A1 (en) 2004-05-04
EP1549353A2 (en) 2005-07-06
DE60331933D1 (de) 2010-05-12
AU2003285863A8 (en) 2004-05-04
MXPA05003705A (es) 2005-08-16
WO2004032865A3 (en) 2004-06-10
US9474801B2 (en) 2016-10-25

Similar Documents

Publication Publication Date Title
DK1549353T3 (da) Anvendelse af alfa(1,3)galactosyltransferaseudtrykkende allogene tumorceller til vaccination mod tumorer
Weiner et al. Genetic vaccines
JP2023133525A (ja) がん及び感染症の治療方法並びに治療用組成物
Crews et al. Prophylactic cancer vaccines engineered to elicit specific adaptive immune response
WO2008057235A3 (en) Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
CY1113394T1 (el) Αντισωματα toy pan-kir2dl νκ υποδοχεα και η χρηση τους στη διαγνωση και τη θεραπεια
TW200513280A (en) Microprojection array immunization patch and method
CN102149391A (zh) 用于治疗肿瘤疾病的组合物和方法
CN105899217A (zh) 癌症疗法中的番木瓜花叶病毒和病毒样颗粒
ATE521629T1 (de) Matrixmetalloproteinase-11-impfstoff
Noh et al. GM-CSF-loaded chitosan hydrogel as an immunoadjuvant enhances antigen-specific immune responses with reduced toxicity
DE69434244D1 (de) Verbesserte krebstherapie
CA3033613A1 (en) Oncolytic rhabdovirus expressing il12
CN105007930B (zh) 用于治疗疾病的同种异体自噬体富集组合物
IL173481A0 (en) Polysaccharide double-layer microcapsules as carriers for biologically active substance oral administration
DE60137146D1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
CN106456730A (zh) 用于诱导或延长细胞之细胞毒性免疫应答的方法的药物
EP1556513A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES MEDIATED BY THE HUMANE PAPILLOMA VIRUS
Macedo et al. Intra-cheek immunization as a novel vaccination route for therapeutic vaccines of head and neck squamous cell carcinomas using plasmo virus-like particles
ES2357548T3 (es) Péptido poli-epitope derivado de timidilato sintasa que tiene actividad inmunológica y antitumoral.
KR20200142028A (ko) 애주번트로서의 버크홀데리아 슈도말레이 복합체 외막 소포체
ES2635516T3 (es) Sensibilización para vacunación con TH1 para inmunoterapia activa
Ye et al. rWTC-MBTA: autologous vaccine prevents metastases via antitumor immune responses
Ye et al. Targeting DNA vaccines to myeloid cells using a small peptide